What is the highest vaccine protection rate in COVID-19, China?

Following the release of the third-phase clinical data of two inactivated vaccines, China Bio and Kexing Zhongwei, of Sinopharm Group, the mid-term analysis of the third-phase clinical trial of China recombinant COVID-19 vaccine (adenovirus vector) jointly developed by Chen Wei, an academician of China Academy of Engineering, and Kangxinuo Bio Co., Ltd. was successfully completed. On February 8, the Pakistani authorities released the latest data of the test.

Up to now, three COVID-19 vaccines in China have published the data of phase III clinical trials.

COVID-19 Vaccine Recombined by Academician Chen Wei: The overall protection effect is 74.8%.

Faisal Sultan, Special Assistant to Pakistani Prime Minister for Health and Wellness, announced that Ad5-nCoV, an adenovirus vector vaccine jointly developed by Academician Chen Wei of the Academy of Military Sciences and Kangxinuo Bio, showed that the protective efficacy of the vaccine against severe COVID-19 after a single injection was 100%, and the overall protective efficacy was 74.8%, without any serious adverse reactions related to the vaccine.

The Ad5-nCoV vaccine developed by Chen Wei's team is the first COVID-19 vaccine in the world to enter the clinical research stage, and it is also one of the only single-needle vaccines in the world with published phase III trial data.

At present, Oxford/AstraZeneca vaccine (AZD 1222), Johnson & Johnson vaccine (Ad26. COV2.S) and Russian "Satellite V" were also developed by the same technical route as Kangxinuo vaccine, among which only Kangxinuo vaccine and Johnson & Johnson vaccine are one shot vaccine. 65438129 October, Johnson & Johnson announced the results of the third phase clinical trial of its vaccine. After 28 days, the total effective rate of COVID-19 vaccine for moderate and severe COVID-19 reached 66%, and the effective rate for preventing serious diseases in all study areas was 85%.

Some immunologists analyzed in an interview with the media that the single-needle vaccination procedure is simple, and more people can be vaccinated at the same time, which is conducive to protecting as many people as possible in the shortest time.

Kexing Zhong COVID-19 Vaccine: The highest protective effect can reach 9 1.25%.

On February 6th, Kexing Holding Biotechnology Co., Ltd. announced that the State Administration of Pharmaceutical Products approved the novel coronavirus inactivated vaccine Kelaifu developed by its subsidiary Beijing Kexing Zhongwei Biotechnology Co., Ltd. to be conditionally listed in China on February 5th.

Since July 2, 20201,Kexing Zhongwei has carried out phase III clinical research in Brazil, Chile in South America, Indonesia in Southeast Asia and Turkey in the Middle East. Through phase III clinical studies in Brazil and Turkey, the protective efficacy of the vaccine against diseases caused by COVID-19 is over 50%, with the highest value of 9 1.25%.

In the phase III clinical trial in Brazil, as of June 65438+February 16, 2020, the protective efficacy of the vaccine was 100.00%, for COVID-19 cases with obvious symptoms and requiring medical intervention, it was 83.70%, and for all COVID-19 cases without medical intervention, it was 50.65%.

The results of phase III clinical trial in Turkey showed that by February 23rd, 2020, the protective effect of two doses of vaccine19 in preventing coronavirus pneumonia was 9 1.25%.

China Bio-COVID-19 Vaccine of Sinopharm Group: The protective efficacy is 79.34%.

On the last day of 2020, 65438+February 3 1 day, the press conference of joint prevention and treatment in the State Council announced that the State Medical and Drug Administration approved the application for registration of COVID-19 inactivated vaccine in China Institute of Biological Products of Sinopharm Group on June 5438+February 30.

On June 30, 2020, 65438+February, Sinopharm announced that the vaccine was safe. After two injections of immunization program, all the vaccinators in the vaccine group produced high titer antibodies, and the positive conversion rate of neutralizing antibodies was 99.52%. The protective effect of the vaccine against diseases caused by COVID-19 infection (coronavirus pneumonia-19) was 79.34%, and the data reached the relevant level of the World Health Organization.

According to public information, the inactivated COVID-19 vaccine produced by Sinopharm Holdings has been tested in three phases in many countries and regions before, and it has been approved for emergency use in China. No serious adverse reactions occurred in emergency use and overseas phase III clinical trials.

How to choose several COVID-19 vaccines in China?

Many countries do not have any vaccines and need to import a lot. At present, there are several vaccines in China. How to choose them?

Shao, a researcher of China CDC and consultant of WHO Vaccine R&D Committee, said in an interview with News 1+ 1 on February 9 that this issue is very important, not only for national decision-making departments, but also for public participation in vaccination. This is a key issue. Although there are five technical routes in China, each vaccine is different in effectiveness, safety and accessibility. From the protection effect, the protection effect of the latest mRNA vaccine is above 90%, and the range of inactivated vaccine and virus vector vaccine is 70% ~ 80%. As far as safety is concerned, medicine is an experimental science. Only through experiments, its safety and confidence depend on how many people and how long it has been tested. Inactivated vaccine has been used by human beings for hundreds of years, and it is used all over the earth, with the highest safety and assurance.